AngioDynamics Q3 Earnings Call Highlights [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
million (now 48% of sales), and management raised full-year net sales and adjusted EBITDA guidance for the third consecutive quarter. Product momentum is concentrated in Auryon (Q3 revenue $16.3M, +17.9% and the 19th straight double-digit quarter); the combined mechanical thrombectomy portfolio grew ~18% with AlphaVac up 47.4% YoY and enrollment started in the APEX-Return pivotal trial; NanoKnife sales rose 21% alongside a new CPT Category I code and expanded EU indications. Margins and cash: gross margin fell 110 bps to 52.9% due to tariffs and a manufacturing transition, but adjusted EBITDA improved to $1.8M and FY adjusted EBITDA guidance was raised to $10–12M; the company had $37.8M in cash, zero debt, and warned a $3–5M inventory build plus $4–6M of tariff costs could make full-year cash flow slightly negative. Interested in AngioDynamics, Inc.? Here are five stocks we like better. AngioDynamics (NASDAQ:ANGO) reported fiscal 2026 third-quarter results that management desc
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- AngioDynamics (ANGO) had its price target lowered by Canaccord Genuity Group Inc. from $18.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- AngioDynamics Growing, But With More Noise Than The Street Likes [Seeking Alpha]Seeking Alpha
- AngioDynamics Inc (ANGO) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued ProfitabilityBusiness Wire
- AngioDynamics (ANGO) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
ANGO
Earnings
- 4/2/26 - Beat
ANGO
Analyst Actions
- 4/6/26 - Canaccord Genuity
ANGO
Sec Filings
- 4/2/26 - Form 10-Q
- 4/2/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- ANGO's page on the SEC website